Medtronic’s MiniMed split attracts massive shareholder demand. Why will only 18.3% of tendered shares be accepted?

Medtronic plc (NYSE: MDT) has reported that its exchange offer involving MiniMed Group, Inc. (NASDAQ: MMED) was oversubscribed, advancing the planned separation of its diabetes technology business through a transaction expected to transfer Medtronic’s entire remaining ownership interest. According to preliminary results announced on October 12, 2026, shareholders tendered approximately 298 million Medtronic shares, substantially exceeding the number the company intends to accept. Medtronic expects to exchange approximately 55 million of its own shares for its remaining 252.8 million MiniMed shares, subject to final processing and confirmation of the exchange results. The transaction is expected to complete the ownership separation, creating a clearer corporate structure for both businesses while introducing a new test of MiniMed’s independent market valuation.

The exchange offer expired at the end of October 9, following a process that allowed eligible Medtronic shareholders to exchange their existing holdings for shares in MiniMed. Because the offer attracted more tendered shares than Medtronic intends to accept, most participating shareholders will have only a portion of their validly tendered shares exchanged, subject to the offer’s specific allocation rules.

Medtronic has estimated a preliminary proration factor of approximately 18.3%, with the final figure expected to be announced on October 14. The result reflects the mechanics of an oversubscribed exchange offer rather than a conventional public share subscription.

Why did Medtronic’s MiniMed exchange offer attract approximately 298 million tendered shares?

The exchange offer provides a mechanism for completing the separation of MiniMed while allowing participating Medtronic shareholders to obtain direct ownership of the diabetes technology business. Under the final exchange ratio, each accepted Medtronic ordinary share will be exchanged for 4.5939 MiniMed shares. The ratio reflects the maximum permitted under the terms of the offer, following the relevant share-price calculation period.

MiniMed completed an initial public offering in March 2026, selling 28 million shares at $20 each. Its shares began trading on Nasdaq on March 6, and the offering closed on March 9. Medtronic retained approximately 90.03% ownership following the flotation, meaning the initial listing established a publicly traded share price without completing the separation of control.

The latest exchange is designed to dispose of that remaining stake. Rather than distributing MiniMed shares to all Medtronic shareholders through a conventional spin-off, the split-off structure allows shareholders to decide whether they want to tender shares and participate in the exchange. Those whose shares are accepted will receive direct exposure to MiniMed, while shareholders who retain Medtronic shares will continue owning the wider medical technology group.

Medtronic launched the offer with terms intended to provide an exchange discount based on the companies’ share prices, subject to the maximum exchange ratio. These terms can make participation attractive under certain market conditions, although the economic outcome depends on relative share prices, the final allocation and subsequent trading performance.

The large number of tendered shares indicates substantial interest in participating in the transaction. It does not necessarily establish a lasting institutional preference for MiniMed over Medtronic because the exchange mechanism can attract investors pursuing different financial or trading strategies.

How does the 18.3% preliminary proration factor affect Medtronic shareholders?

According to the company’s exchange agent, Equiniti Trust Company, approximately 298,024,452 Medtronic ordinary shares were validly tendered and not withdrawn before the offer expired. That total included approximately 93.3 million shares tendered under guaranteed delivery procedures. It also included approximately 757,890 shares tendered by qualifying odd-lot shareholders who are exempt from the ordinary proration process when they satisfy the applicable conditions.

Medtronic intends to accept 55,032,401 ordinary shares in exchange for 252,813,348 MiniMed shares. The company has estimated that approximately 18.3% of tendered Medtronic shares will be accepted, assuming shares tendered through guaranteed delivery procedures are delivered as required.

For a shareholder who validly tendered 1,000 Medtronic shares and is subject to ordinary proration, an illustrative acceptance rate of 18.3% would mean approximately 183 shares being accepted. Applying the exchange ratio would result in approximately 841 MiniMed shares before accounting for final allocation mechanics and any treatment of fractional entitlements. This is an illustrative calculation rather than a statement of any individual shareholder’s confirmed allocation.

Shares tendered but not accepted will be returned to participating shareholders. Consequently, an investor who offered an entire position may emerge holding both Medtronic and MiniMed shares, rather than converting the full investment into the diabetes technology business.

The final proration factor can change depending on the outcome of guaranteed delivery procedures and other allocation requirements. Medtronic expects to announce the confirmed figure on October 14, with the return of unaccepted shares following the final determination.

The completed exchange is expected to reduce Medtronic’s ordinary share count by accepting approximately 55 million shares. A lower outstanding share count can affect future per-share financial measures, although the wider financial consequences must also reflect the removal of MiniMed’s results from the consolidated business and any other relevant accounting adjustments.

What does the MiniMed separation mean for Medtronic’s long-term business strategy?

Medtronic’s decision to separate MiniMed reflects a broader effort to concentrate its corporate resources on its remaining medical technology operations. These include cardiovascular devices, neuroscience technologies and surgical products, which management has identified as important areas for future investment and growth. Removing its controlling ownership in MiniMed should provide a clearer distinction between the operating performance of the two businesses.

The diabetes technology market has its own commercial characteristics, including competition in insulin delivery systems, continuous glucose monitoring integration and automated diabetes management. Product development, clinical evidence, regulatory approvals and reimbursement considerations can influence adoption at different rates from those affecting cardiac and surgical equipment. Operating independently gives MiniMed a dedicated public-market identity through which investors can assess these opportunities.

Medtronic’s latest reported first-quarter fiscal 2027 results provide context for the company’s broader operations. For the quarter ended July 31, 2026, Medtronic reported approximately $9.8 billion in revenue, up 13.7% on a reported and organic basis. The company also reported non-GAAP diluted earnings per share of $1.45 and increased its fiscal 2027 guidance at the time.

Those figures require careful interpretation because MiniMed remained controlled and consolidated during the reporting period. Medtronic’s future financial statements after completing the separation may therefore have a different revenue and earnings composition. Comparing the pre-separation and post-separation groups without adjusting for the transaction could produce misleading growth conclusions.

The separation may make capital allocation more transparent because management will be able to focus on businesses remaining within Medtronic’s portfolio. However, removing the diabetes business also eliminates direct participation in MiniMed’s future operating growth, apart from any transitional contractual relationships that continue after the ownership separation.

The commercial case for Medtronic will depend on whether the remaining portfolio can deliver durable revenue growth, attractive operating margins and sufficient cash generation to support research, product launches and other strategic investment.

How strong is MiniMed’s standalone diabetes technology business after its March 2026 IPO?

MiniMed enters the final stages of separation with an established commercial business rather than operating as an early-stage medical technology developer. For the first quarter of fiscal 2027, ended July 31, 2026, the company reported net sales of approximately $843 million, representing 17% reported growth and 16% organic growth from the corresponding prior-year period. The results indicate continued commercial momentum in insulin delivery technologies and related diabetes management products.

United States net sales increased approximately 13%, while international sales grew 18% on a reported basis and 17% organically. The geographic performance provides evidence that MiniMed’s growth is not limited to a single market, although product launches, reimbursement conditions and distribution arrangements can produce different growth rates between regions.

MiniMed has also been advancing its product pipeline, including regulatory work involving the MiniMed Fit and MiniMed Flex systems. Its September financial update reported progress across several development programmes and an increase in its fiscal 2027 organic revenue growth guidance. These developments may support the company’s competitive position, provided future regulatory and commercial milestones are achieved.

As an independent listed company, MiniMed will compete for investor attention against other diabetes technology businesses, including manufacturers of insulin pumps and continuous glucose monitoring systems. Commercial performance will be influenced by product reliability, ease of use, healthcare provider adoption, reimbursement arrangements and the pace of technological innovation.

The company’s March initial public offering generated approximately $538 million in net proceeds after underwriting discounts, commissions and estimated offering expenses. MiniMed indicated that part of those proceeds would support general corporate purposes, with the remainder used to repay intercompany debt owed to Medtronic.

Financial independence does not immediately eliminate operational connections between the businesses. Medtronic and MiniMed have established transitional service arrangements intended to support the separation, including services generally not expected to extend beyond 24 months after the IPO. The process of replacing those arrangements with independently managed systems will form part of MiniMed’s operational development.

Why did Medtronic and MiniMed shares move in opposite directions after the exchange announcement?

Medtronic shares closed at approximately $91.93 on October 12, gaining 3.9% during the session. MiniMed shares moved in the opposite direction, falling approximately 4.6% to $18.81. The contrasting movements occurred as investors assessed the exchange process, the approaching confirmation of share allocations and the businesses’ respective standalone prospects.

MiniMed’s closing price was below its March IPO price of $20, although a direct comparison does not account for the broader market environment or the mechanics of the subsequent exchange offer. The stock may experience trading volatility as newly distributed shares become available to investors who participated in the transaction.

A large exchange offer can create temporary trading dynamics unrelated to the underlying operating business. Participating shareholders may have different intentions for their new MiniMed holdings, while investors who retain Medtronic shares may reassess the company’s prospective earnings mix. These factors complicate attempts to attribute the entire movement in either share price to one explanation.

For Medtronic, the next financial reporting periods should provide evidence of how the remaining portfolio performs after the diabetes business is removed from its consolidated results. Investors will need to assess revenue growth, operating margins, capital allocation and share-count changes using financial figures that reflect the new corporate structure.

For MiniMed, the more important long-term measures will be sales growth, profitability, cash generation and the commercial success of its product pipeline. The company’s independent status may improve strategic focus, but it will also require management to demonstrate that its operating model can sustain growth without relying indefinitely on Medtronic’s infrastructure.

The exchange offer marks a major step toward the completion of Medtronic’s diabetes business separation. Preliminary demand for participation has been strong, but the immediate shareholder mechanics should not be mistaken for evidence that either company’s valuation is necessarily attractive. The next milestones are confirmation of the final proration factor on October 14, completion of the exchange and subsequent financial disclosures showing how both companies perform under their separate ownership structures.

What are the key takeaways from the Medtronic and MiniMed exchange offer results?

• Medtronic’s MiniMed exchange offer expired on October 9, 2026.
• Preliminary results confirmed that the offer was oversubscribed.
• Approximately 298 million Medtronic shares were tendered.
• Medtronic intends to accept approximately 55 million of those shares.
• Shareholders receive 4.5939 MiniMed shares for each accepted Medtronic share.
• The preliminary proration factor is approximately 18.3%.
• Medtronic intends to exchange its entire remaining MiniMed ownership interest.
• MiniMed reported first-quarter fiscal 2027 net sales of approximately $843 million.
• Medtronic and MiniMed shares moved in opposite directions on October 12.
• The final proration factor is expected on October 14, ahead of the separation’s completion.